Wei Sheng1,2, Long Chen3, Huijun Wang1,2, Xiaojing Ma1,2, Duan Ma2,4, Guoying Huang1,2. 1. Children Hospital of Fudan University, Shanghai, China. 2. Shanghai Key Laboratory of Prevention and Intervention of Birth Defects, Shanghai, China. 3. Department of Forensic Medicine, Fudan University, Shanghai, China. 4. Department of Biochemistry and Molecular Biology, Shanghai Medical College, Fudan University, Shanghai, China.
Abstract
BACKGROUND: ZFPM2 gene plays an important role in heart morphogenesis and development of coronary vessels from epicardium, however, little is known regarding its epigenetic regulation in the pathogenesis of tetralogy of fallot (TOF). METHODS: The methylation levels of ZFPM2 gene were measured by MassArray (Sequenom, San Diego, CA) and bisulfite sequencing polymerase chain reaction (PCR) (BSP). Real-time PCR was performed to analyze the mRNA levels for ZFPM2 gene in the myocardium of TOF. RESULTS: The methylation levels in the CpG island shore of ZFPM2 promoter were significantly higher in patients with TOF, with a median of 80.32% (interquartile range (IQR): 73.54-85.75%, N = 42), as compared to 59.63% in controls (IQR: 44.79-73.83%; P = 0.0186, N = 6). No significant difference was observed in the methylation status at the CpG island of ZFPM2 promoter. The ZFPM2 mRNA levels were significantly lower in patients with TOF compared to that in the controls (P < 0.05). The aberrant methylation values of ZFPM2 were negatively associated with significant changes in its mRNA level (r = -0.40, P = 0.008, N = 42). CONCLUSION: Aberrant methylation status at the promoter CpG island shore of ZFPM2 gene may be associated with its gene transcription regulation in the TOF patients.
BACKGROUND:ZFPM2 gene plays an important role in heart morphogenesis and development of coronary vessels from epicardium, however, little is known regarding its epigenetic regulation in the pathogenesis of tetralogy of fallot (TOF). METHODS: The methylation levels of ZFPM2 gene were measured by MassArray (Sequenom, San Diego, CA) and bisulfite sequencing polymerase chain reaction (PCR) (BSP). Real-time PCR was performed to analyze the mRNA levels for ZFPM2 gene in the myocardium of TOF. RESULTS: The methylation levels in the CpG island shore of ZFPM2 promoter were significantly higher in patients with TOF, with a median of 80.32% (interquartile range (IQR): 73.54-85.75%, N = 42), as compared to 59.63% in controls (IQR: 44.79-73.83%; P = 0.0186, N = 6). No significant difference was observed in the methylation status at the CpG island of ZFPM2 promoter. The ZFPM2 mRNA levels were significantly lower in patients with TOF compared to that in the controls (P < 0.05). The aberrant methylation values of ZFPM2 were negatively associated with significant changes in its mRNA level (r = -0.40, P = 0.008, N = 42). CONCLUSION: Aberrant methylation status at the promoter CpG island shore of ZFPM2 gene may be associated with its gene transcription regulation in the TOFpatients.
Authors: Vadim Yuferov; David A Nielsen; Orna Levran; Matthew Randesi; Sara Hamon; Ann Ho; Susan Morgello; Mary Jeanne Kreek Journal: Pharmacogenet Genomics Date: 2011-04 Impact factor: 2.089
Authors: Alessandro De Luca; A Sarkozy; R Ferese; F Consoli; F Lepri; M L Dentici; P Vergara; A De Zorzi; P Versacci; M C Digilio; B Marino; B Dallapiccola Journal: Clin Genet Date: 2010-08-02 Impact factor: 4.438
Authors: Mathias Ehrich; Julia Turner; Peter Gibbs; Lara Lipton; Mara Giovanneti; Charles Cantor; Dirk van den Boom Journal: Proc Natl Acad Sci U S A Date: 2008-03-19 Impact factor: 11.205
Authors: Mary Ella Pierpont; Craig T Basson; D Woodrow Benson; Bruce D Gelb; Therese M Giglia; Elizabeth Goldmuntz; Glenn McGee; Craig A Sable; Deepak Srivastava; Catherine L Webb Journal: Circulation Date: 2007-05-22 Impact factor: 29.690